权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Measurement of antibodies against tumor suppressor gene products in health screening for lung cancer

肺癌健康筛查中抑癌基因产物抗体的测定

基本信息

批准号：
14570550
负责人：
SHIMIZU Eiji
金额：
$ 1.73万
依托单位：
Tottori University Faculty of Medicine
依托单位国家：
日本
项目类别：
Grant-in-Aid for Scientific Research (C)
财政年份：
2002
资助国家：
日本
起止时间：
2002 至 2003
项目状态：
已结题

项目摘要

To establish serum markers for early diagnosis of lung cancer, we developed methods to detect autoantibodies against tumor suppressor gene products. In addition, we conducted a large scale survey to confirm the performance of these markers to detect lung cancer among healthy people. First, we developed an immunoblotting assay against bacterially generated GST-RB fusion proteins. Using this assay, we examined 45 sera from lung cancer patients and 30 healthy volunteers. We found 13.3% of lung cancer patients had serum antibodies against GST-Rb fusion proteins, while none of 30 normal volunteers had these antibodies. Secondly, we developed Enzyme-Linked Immunosorbent Assay (ELISA) for detecting anti-Rb antibodies to facilitate measurement a lot of samples. This ELISA system could detect elevated anti-Rb antibodies in serum of lung cancer patients, but not in normal volunteers. These results indicated the usefulness of our measuring systems for anti-Rb antibodies. Thirdly, to study the performance of these measuring systems in health screening for lung cancer, we got the approval of the ethical committee of Tottori University, and of local self-governing bodies in Tottori prefecture. After that, we started to recruit healthy volunteers who provide their serum and information of disease experience in group health examination settings. We are planning to continue this study for more three years. In summary, supported by this grant, we made two sensitive methods to detect autoantibodies against tumor suppressor gene products, verified their usefulness in lung cancer patients as tumor makers, and started mass survey to confirm their performance in health screening for lung cancer. We believe this will lead to the development of a new serum indicator for early detection of lung cancer.

为了建立肺癌早期诊断的血清标志物，我们开发了检测抗肿瘤抑制基因产物的自身抗体的方法。此外，我们进行了一项大规模调查，以确认这些标志物在健康人群中检测肺癌的性能。首先，我们开发了针对细菌产生的GST-RB融合蛋白的免疫印迹分析。用此方法检测了45例肺癌患者和30例健康志愿者的血清。我们发现13.3%的肺癌患者血清中有抗GST-Rb融合蛋白的抗体，而30名正常志愿者中没有这些抗体。其次，我们开发了检测抗Rb抗体的酶联免疫吸附试验（ELISA），以方便大量样本的测量。该ELISA检测系统能检测出肺癌患者血清中抗Rb抗体的升高，但不能检测到正常人血清中抗Rb抗体的升高。这些结果表明，我们的抗Rb抗体的测量系统的有用性。第三，为了研究这些测量系统在肺癌健康筛查中的性能，我们得到了鸟取大学伦理委员会和鸟取县地方自治团体的批准。之后，我们开始招募健康志愿者，他们在团体健康检查设置中提供他们的血清和疾病经历信息。我们计划继续这项研究三年以上。综上所述，在该基金的支持下，我们建立了两种灵敏的检测肿瘤抑制基因产物自身抗体的方法，验证了它们作为肿瘤标记物在肺癌患者中的有用性，并开始进行大规模调查，以确认它们在肺癌健康筛查中的性能。我们相信这将导致一种新的血清指标的发展，用于肺癌的早期检测。